Volker J. Mobus

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.

Journal: The Lancet regional health. Europe

Published: September 02, 2024

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 17, 2024

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.

Journal: NPJ breast cancer

Published: March 13, 2024

Clinical Axillary Staging in Breast Cancer Patients Using Ultrasound Imaging.

Clinical Axillary Staging in Breast Cancer Patients Using Ultrasound Imaging.

Journal: Breast care (Basel, Switzerland)

Published: November 14, 2023

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.

Journal: Breast cancer research and treatment

Published: October 20, 2023

Breast Cancer Outcome: What Have We Achieved.

Breast Cancer Outcome: What Have We Achieved.

Journal: Breast care (Basel, Switzerland)

Published: September 08, 2023

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 07, 2022

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.

Journal: Breast (Edinburgh, Scotland)

Published: August 04, 2022

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.

Journal: Cancers

Published: December 01, 2021

Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.

Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.

Journal: Geburtshilfe und Frauenheilkunde

Published: November 01, 2021

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 29, 2021

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.

Journal: BMC cancer

Published: September 16, 2021

Showing 1-12 of 69

Last Updated: 09/26/2026